1. Home
  2. MVBF vs TNXP Comparison

MVBF vs TNXP Comparison

Compare MVBF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MVB Financial Corp.

MVBF

MVB Financial Corp.

HOLD

Current Price

$27.79

Market Cap

333.7M

Sector

Finance

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$19.20

Market Cap

231.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVBF
TNXP
Founded
1997
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
333.7M
231.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MVBF
TNXP
Price
$27.79
$19.20
Analyst Decision
Strong Buy
Buy
Analyst Count
5
1
Target Price
$27.60
$70.00
AVG Volume (30 Days)
74.4K
761.3K
Earning Date
10-29-2025
11-10-2025
Dividend Yield
2.44%
N/A
EPS Growth
73.99
N/A
EPS
2.45
N/A
Revenue
$167,853,000.00
$10,299,000.00
Revenue This Year
N/A
$14.79
Revenue Next Year
$14.06
$933.49
P/E Ratio
$11.37
N/A
Revenue Growth
18.75
N/A
52 Week Low
$15.59
$6.76
52 Week High
$28.72
$130.00

Technical Indicators

Market Signals
Indicator
MVBF
TNXP
Relative Strength Index (RSI) 62.40 56.16
Support Level $26.52 $18.59
Resistance Level $28.72 $20.24
Average True Range (ATR) 0.69 1.29
MACD 0.12 0.60
Stochastic Oscillator 72.70 81.63

Price Performance

Historical Comparison
MVBF
TNXP

About MVBF MVB Financial Corp.

MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: